Comparing two treatments for head and neck cancer before chemoradiation
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests two different drug combos—one using an EGFR-targeted therapy alone, the other adding an immunotherapy—before standard chemoradiation for locally advanced head and neck cancer. The goal is to see which approach works better without prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have head and neck cancer that is locally advanced (not spread to distant parts of the body).
- You need to be in good enough health to have a daily activity level of 0 or 1 on a standard scale (able to do light work).
- Your tumor must be measurable on a CT scan or MRI.
- You must be able to receive cisplatin chemotherapy (a common treatment for head and neck cancer).
- You should not have significant hearing loss (at most mild hearing trouble).
- You must not have had any prior chemotherapy, immunotherapy, targeted therapy, or radiation for head and neck cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two or three drugs given before surgery to shrink locally advanced head and neck cancer. The goal is to see if this approach can improve outcomes for patients whose tumors have a specific protein called EGFR.
This trial tests a new immunotherapy drug (pucotenlimab) combined with chemotherapy before surgery for head and neck cancer. The goal is to see if this combination shrinks the tumor and improves outcomes for patients with locally advanced disease.
This trial tests a combination of two drugs given before surgery for advanced mouth or throat cancer. The drugs may help shrink tumors and improve the chance of successful surgery. It is specifically for patients whose cancer has high levels of PD-L1 and EGFR proteins.
This trial is testing a new combination of drugs given before surgery (neoadjuvant) and followed by radiation after surgery to treat locally advanced head and neck cancer. The goal is to see if this approach is safe and effective, and may improve outcomes for patients who have not yet been treated.
This trial is testing a combination of two drugs (becotatug vedotin and pucotenlimab) given before surgery to shrink recurrent head and neck cancer that has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this approach helps make the tumor removable and improves outcomes.
This trial tests a combination of two drugs (pucotenlimab and becotatug vedotin) given before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve outcomes when combined with surgery.
Hear when a new Locally Advanced Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.